[SaneVax: According to The Financial Times, only 32% of young women in the United States eligible to take Gardasil are completing the series. According to Merck, the FDA and the CDC this has nothing to do with the fact that Gardasil is associated with 66.3% of all deaths and 81.2% of all permanent disabilities reported to VAERS in the same cohort since Gardasil was approved for use. Can you imagine the potential consequences if the uptake were greater?]
Merck’s Gardasil, GSK’s Cervarix HPV vaccines see poor adherence, experts question overall response
By Juliana Wexler
Merck’s Gardasil, a human papillomavirus (HPV) vaccine, has poor adherence and more data is required on the effects of receiving fewer than the full three-dose regimen, according to experts interviewed by BioPharm Insight.
A recent Centers for Disease Control and Prevention (CDC) report indicated only 32% of US females aged 13 to 17 received all three doses of an HPV vaccine in 2010. GlaxoSmithKline’s Cervarix is the other marketed HPV vaccine and is also administered as a three-dose regimen.
HPV is a sexually transmitted infection spread via skin that can lead to genital warts or cancers of the genitals or anus. Almost all cases of cervical cancers are caused by HPV, although 90% of HPV infections clear on their own. HPV vaccines prevent infection against the specific HPV genotypes included in the vaccine.
While Gardasil and Cervarix are both approved for use in females, Gardasil is also approved for use in males. The overarching reason to vaccinate males is to prevent them from transmitting HPV to females, an investigator on Merck’s HPV vaccines said.
To further its reach in HPV, Merck is developing another vaccine, V503, which protects against five more cancer-causing HPV genotypes than the two in Gardasil and Cervarix.
Read the entire article here.